Search Page

1

Cite

Share

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: I. Development and Description of the Pause Marker.

Shriberg LD, Strand EA, Fourakis M, Jakielski KJ, Hall SD, Karlsson HB, Mabie HL, McSweeny JL, Tilkens CM, Wilson DL. Shriberg LD, et al. Among authors: hall sd. J Speech Lang Hear Res. 2017 Apr 14;60(4):S1096-S1117. doi: 10.1044/2016_JSLHR-S-15-0296. J Speech Lang Hear Res. 2017. PMID: 28384779 Free PMC article. Review.

Cite

Share

2

Cite

Share

Overview of the Genetics of Alcohol Use Disorder.

Tawa EA, Hall SD, Lohoff FW. Tawa EA, et al. Among authors: hall sd. Alcohol Alcohol. 2016 Sep;51(5):507-14. doi: 10.1093/alcalc/agw046. Epub 2016 Jul 21. Alcohol Alcohol. 2016. PMID: 27445363 Free PMC article. Review.

Cite

Share

3

Cite

Share

Irreversible enzyme inhibition kinetics and drug-drug interactions.

Mohutsky M, Hall SD. Mohutsky M, et al. Among authors: hall sd. Methods Mol Biol. 2014;1113:57-91. doi: 10.1007/978-1-62703-758-7_5. Methods Mol Biol. 2014. PMID: 24523109 Review.

Cite

Share

4

Cite

Share

Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance.

Coutant DE, Hall SD. Coutant DE, et al. Among authors: hall sd. J Clin Pharmacol. 2018 Jul;58(7):849-863. doi: 10.1002/jcph.1093. Epub 2018 Mar 5. J Clin Pharmacol. 2018. PMID: 29505093 Review.

Cite

Share

5

Cite

Share

Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.

Guo Y, Lucksiri A, Dickinson GL, Vuppalanchi RK, Hilligoss JK, Hall SD. Guo Y, et al. Among authors: hall sd. Clin Pharmacol Ther. 2020 Jan;107(1):246-256. doi: 10.1002/cpt.1596. Epub 2019 Sep 12. Clin Pharmacol Ther. 2020. PMID: 31356678 Free PMC article. Clinical Trial.

Cite

Share

6

Cite

Share

Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD. Jones HM, et al. Among authors: hall sd. Clin Pharmacol Ther. 2015 Mar;97(3):247-62. doi: 10.1002/cpt.37. Epub 2015 Jan 9. Clin Pharmacol Ther. 2015. PMID: 25670209 Review.

Cite

Share

7

Cite

Share

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.

Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD. Coutant DE, et al. Among authors: hall sd. Clin Pharmacol Ther. 2015 Jul;98(1):76-86. doi: 10.1002/cpt.128. Epub 2015 May 19. Clin Pharmacol Ther. 2015. PMID: 25808023 Review.

Cite

Share

8

Cite

Share

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.

Posada MM, Morse BL, Turner PK, Kulanthaivel P, Hall SD, Dickinson GL. Posada MM, et al. Among authors: hall sd. J Clin Pharmacol. 2020 Jul;60(7):915-930. doi: 10.1002/jcph.1584. Epub 2020 Feb 20. J Clin Pharmacol. 2020. PMID: 32080863 Free PMC article.

Cite

Share

9

Cite

Share

High Affinity Binding of N2-Modified Guanine Derivatives Significantly Disrupts the Ligand Binding Pocket of the Guanine Riboswitch.

Matyjasik MM, Hall SD, Batey RT. Matyjasik MM, et al. Among authors: hall sd. Molecules. 2020 May 13;25(10):2295. doi: 10.3390/molecules25102295. Molecules. 2020. PMID: 32414072 Free PMC article.

Cite

Share

10

Cite

Share

Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion.

Morse BL, Alberts JJ, Posada MM, Rehmel J, Kolur A, Tham LS, Loghin C, Hillgren KM, Hall SD, Dickinson GL. Morse BL, et al. Among authors: hall sd. CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):664-675. doi: 10.1002/psp4.12447. Epub 2019 Aug 1. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31250974 Free PMC article.

Cite

Share